Atogepant for migraine prevention: a meta-analysis of safety and efficacy in adults.

ABSTRACT:

Background

Migraine is a neurological condition marked by frequent headaches, which tends to be accompanied by nausea and vomiting in severe instances. Injectable therapies for migraine, such as monoclonal antibodies that target calcitonin gene-related peptide (CGRP), have proven to be effective and safe. While various oral drugs are available, none have been developed for migraines. Patients prefer oral therapies because they are easier to use, making atogepant, an orally accessible small-molecule CGRP receptor antagonist, a possible alternative.

Objectives

This systematic review and meta-analysis compared the safety and effectiveness of atogepant with placebo in treating migraine.

Methods

Adhering to the PRISMA guidelines, we meticulously gathered randomized control

SUBMITTER: Raja A 

PROVIDER: S-EPMC11466836 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature